Browsing Tag
Ryoncil
11 posts
Mesoblast (ASX: MSB) reports US$99m cash after stronger Ryoncil sales and lower expenditure
Mesoblast has reported higher year-on-year revenue from its approved cell therapy Ryoncil and a sharp reduction in operating cash expenditure, although sequential sales declined following a stronger June quarter.
Mesoblast rises as FDA clears new commercial potency assay for Ryoncil
Mesoblast Limited shares rose after the United States Food and Drug Administration approved an additional potency assay for commercial Ryoncil manufacturing, strengthening quality controls as the Australian biotechnology company scales its first marketed cell therapy.
Mesoblast revenue jumps sevenfold to $120m as Ryoncil turns cell therapy into a commercial business
Mesoblast generated $120.3 million of FY26 revenue, including $115.2 million from Ryoncil, while narrowing its loss 44% and advancing adult GVHD, Duchenne, back pain and heart-failure programmes.
Mesoblast completes 350-patient Phase 3 treatment as mid-2027 back pain readout becomes next valuation test
Mesoblast has completed treatment of 350 Phase 3 back pain patients, putting rexlemestrocel-L on course for a pivotal mid-2027 efficacy readout.
Mesoblast (ASX: MSB; Nasdaq: MESO) CEO invests A$2.73m as Ryoncil growth shifts focus to execution
Mesoblast Chief Executive Silviu Itescu has paid A$2.73 million to increase his ownership, adding an alignment signal as Ryoncil sales and late-stage programs reshape the company.
Mesoblast (ASX: MSB) clears key treatment milestone ahead of mid-2027 back pain trial readout
Mesoblast has treated at least 300 patients in MSB-DR004, starting the final 12-month clock towards a mid-2027 readout and potential United States filing. The milestone strengthens execution visibility, but it does not provide new efficacy data.
Mesoblast stock gains as Ryoncil revenue hits US$115m in first launch year
Mesoblast Ryoncil revenue hits US$115m in its first launch year. Read how ASX:MSB’s biotech story is shifting from promise to sales.
Cats finally get a disease-modifying therapy candidate as Gallant pilot data clears the bar and FDA opens the fast lane
Gallant reports positive randomised trial data for feline osteoarthritis stem cell therapy and wins FDA expanded conditional approval eligibility. Read the full analysis.
Mesoblast (ASX: MSB) ramps up GVHD play with record Ryoncil revenue and fresh $125m credit line
Ryoncil sales surged 60 percent for Mesoblast in Q4. Read how its $125M refinancing plan could reshape capital efficiency and future cell therapy expansion.
FDA grants orphan drug exclusivity to Mesoblast’s Ryoncil for pediatric SR-aGvHD
Find out how Mesoblast's FDA approval for Ryoncil in pediatric SR-aGvHD sets a new benchmark in stem cell therapy and market exclusivity strategy.